The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.
Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.
The RT-PCR-based test, which runs on Becton Dickinson's BD Max system, simultaneously detects SARS-CoV-2, influenza A and B, and respiratory syncytial virus.
According to the Wall Street Journal, Becton Dickinson is investigating reports from nursing homes regarding false positive results from its rapid COVID-19 test.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
